Wells Fargo's Brian Abrahams likes the news on Vertex (VRTX), saying it cleanly validates the...


Wells Fargo's Brian Abrahams likes the news on Vertex (VRTX), saying it cleanly validates the efficacy of it's corrector/potentiator approach, and meaningfully increases the likelihood of success in its '809/Kalydeco Phase III program, and at worst gives VRTX a high probability shot for '661/Kalydeco to capture this multi-billion dollar opportunity. As such, Abrahams sees significant upside potential from the news.

From other sites
Comments (1)
  • rootbeer
    , contributor
    Comments (321) | Send Message
     
    This can be a hideous disease. Any parent with a child afflicted with CF due to one or two copies of F508del will want to give the child a chance at achieving a 9 percent improvement in overall lung function. If started early in life, this could translate into several years of additional life expectancy by delaying the onset and mitigating the severity of lung scarring. Good news for CF patients and the owners of VRTX.
    18 Apr 2013, 06:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs